TriangleHEALTH PROFESSIONAL · SOURCE READING
Treatment Options for Second-Line Therapy for Stage IV Renal Cell Cancer
Source: Renal Cell Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 13, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Context: Treatment of Stage IV and Recurrent Renal Cell Cancer
Treatment options for second-line therapy for stage IV renal cell cancer include:
Nivolumab (for patients previously treated with sunitinib, pazopanib, sorafenib, and/or axitinib).[22]
Lenvatinib plus everolimus (for patients previously treated with sunitinib, pazopanib, cabozantinib, axitinib, or sorafenib).[23]
Source links and citations
Cabozantinib (for patients previously treated with sunitinib, pazopanib, sorafenib, or axitinib).[24]
Source links and citations
Belzutifan.[25]
Source links and citations
Palliative EBRT.
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Not medical advice